Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 22904336.
- Also identified by DOI 10.1093/infdis/jis510 and PMC identifier 3529603.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progressive vaccinia (PV) is a rare but potentially lethal complication that develops in smallpox vaccine recipients with severely impaired cellular immunity. We describe a patient with PV who required treatment with vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001. We describe the various molecular, pharmacokinetic, and immunologic studies that provided guidance to escalate and then successfully discontinue therapy. Despite development of resistance to ST-246 during treatment, the patient had resolution of PV. This case demonstrates the need for continued development of novel anti-orthopoxvirus pharmaceuticals and the importance of both intensive and timely clinical and laboratory support in management of PV.
Medical subject headings
- Antibodies, Viral
- Antiviral Agents
- Benzamides
- Cytosine
- Isoindoles
- Organophosphonates
- Vaccinia
- Vaccinia virus